Galena Biopharma Company Profile (NASDAQ:GALE)

About Galena Biopharma (NASDAQ:GALE)

Galena Biopharma logoGalena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GALE
  • CUSIP: N/A
  • Web: www.galenabiopharma.com
Capitalization:
  • Market Cap: $22.18 million
  • Outstanding Shares: 37,435,000
Average Prices:
  • 50 Day Moving Avg: $0.59
  • 200 Day Moving Avg: $1.32
  • 52 Week Range: $0.52 - $49.80
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.69
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.73 per share
  • Price / Book: 0.81
Profitability:
  • EBIDTA: ($27,830,000.00)
  • Return on Equity: -115.12%
  • Return on Assets: -27.37%
Debt:
  • Current Ratio: 1.05%
  • Quick Ratio: 1.05%
Misc:
  • Average Volume: 1.19 million shs.
  • Beta: 2.72
  • Short Ratio: 2.55
 

Frequently Asked Questions for Galena Biopharma (NASDAQ:GALE)

What is Galena Biopharma's stock symbol?

Galena Biopharma trades on the NASDAQ under the ticker symbol "GALE."

How were Galena Biopharma's earnings last quarter?

Galena Biopharma Inc (NASDAQ:GALE) announced its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.13. During the same period in the prior year, the company earned ($0.07) EPS. View Galena Biopharma's Earnings History.

Where is Galena Biopharma's stock going? Where will Galena Biopharma's stock price be in 2017?

5 brokers have issued 12-month target prices for Galena Biopharma's stock. Their predictions range from $0.34 to $5.00. On average, they expect Galena Biopharma's stock price to reach $3.37 in the next year. View Analyst Ratings for Galena Biopharma.

What are analysts saying about Galena Biopharma stock?

Here are some recent quotes from research analysts about Galena Biopharma stock:

  • 1. According to Zacks Investment Research, "Galena Biopharma, Inc. is a biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Galena Biopharma, Inc., formally known as RXi Pharmaceuticals Corporation, is based in Portland, Oregon. " (5/16/2017)
  • 2. FBR & Co analysts commented, "On January 31, Galena Biopharma announced that Mark W. Schwartz, Ph.D., resigned as the company's president, CEO, and member of the board of directors, effective immediately. An interim CEO, who will oversee Galena as it explores strategic alternatives with assistance from an independent advisory firm, is expected to be appointed in the next several weeks. At this point, it is not certain whether Galena will continue clinical development of its pipeline on its own, outlicense its assets, or undergo restructuring of its corporate operations before a final decision is made in 2H17. We believe the high value of Galena's pipeline assets remains under-appreciated; however, due to near-term uncertainty, we are moving to the sidelines and lowering our rating from Outperform to Market Perform with a new price target of $4 versus our previous $11 price target." (2/6/2017)

Are investors shorting Galena Biopharma?

Galena Biopharma saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 6,082,629 shares, an increase of 24.3% from the March 31st total of 4,894,724 shares. Based on an average trading volume of 1,083,145 shares, the days-to-cover ratio is presently 5.6 days. Approximately 19.9% of the company's shares are sold short.

Who are some of Galena Biopharma's key competitors?

Who owns Galena Biopharma stock?

Galena Biopharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.45%) and Vanguard Group Inc. (3.67%). View Institutional Ownership Trends for Galena Biopharma.

Who bought Galena Biopharma stock? Who is buying Galena Biopharma stock?

Galena Biopharma's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Vanguard Group Inc.. View Insider Buying and Selling for Galena Biopharma.

How do I buy Galena Biopharma stock?

Shares of Galena Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Galena Biopharma stock cost?

One share of Galena Biopharma stock can currently be purchased for approximately $0.59.

Analyst Ratings

Consensus Ratings for Galena Biopharma (NASDAQ:GALE) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $3.37 (468.34% upside)

Analysts' Ratings History for Galena Biopharma (NASDAQ:GALE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/6/2017FBR & CoDowngradeOutperform -> Market Perform$11.00 -> $4.00N/AView Rating Details
2/2/2017Maxim GroupDowngradeBuy -> HoldN/AView Rating Details
9/20/2016S&P Equity ResearchLower Price Target$0.39 -> $0.34N/AView Rating Details
6/29/2016Noble FinancialDowngradeBuy -> HoldN/AView Rating Details
6/29/2016Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
6/9/2016Roth CapitalReiterated RatingBuy$5.00N/AView Rating Details
1/22/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$4.00N/AView Rating Details
12/8/2015Cantor FitzgeraldUpgradeSell -> Hold$2.00N/AView Rating Details
8/7/2015MLV & Co.Reiterated RatingBuy$5.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Galena Biopharma (NASDAQ:GALE)
Earnings by Quarter for Galena Biopharma (NASDAQ:GALE)
Earnings History by Quarter for Galena Biopharma (NASDAQ:GALE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.22)($0.09)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.05)($0.02)ViewListenView Earnings Details
8/9/2016Q216($0.06)$0.05ViewN/AView Earnings Details
5/10/2016Q1($0.06)($0.07)ViewListenView Earnings Details
3/10/2016Q4($0.05)($0.07)$2.61 millionViewListenView Earnings Details
11/9/2015Q315($0.07)($0.11)$4.22 millionViewListenView Earnings Details
8/6/2015Q215($0.09)($0.07)$3.54 million$3.38 millionViewN/AView Earnings Details
5/7/2015Q115($0.09)($0.08)$3.47 million$2.75 millionViewListenView Earnings Details
3/5/2015Q414($0.12)($0.09)$2.58 million$3.20 millionViewN/AView Earnings Details
11/3/2014Q314($0.13)($0.05)$2.66 million$1.60 millionViewN/AView Earnings Details
8/11/2014Q214($0.09)($0.17)$2.99 million$2.30 millionViewN/AView Earnings Details
5/6/2014Q1($0.10)($0.10)$2.09 million$2.17 millionViewN/AView Earnings Details
3/17/2014Q413($0.09)($0.46)$1.62 million$1.32 millionViewN/AView Earnings Details
8/8/2013Q213($0.10)($0.11)ViewN/AView Earnings Details
3/12/2013Q4 2012($0.62)($0.53)ViewN/AView Earnings Details
11/13/2012Q312($0.09)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Galena Biopharma (NASDAQ:GALE)
2017 EPS Consensus Estimate: ($2.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.98)($0.98)($0.98)
Q2 20171($0.94)($0.94)($0.94)
Q3 20171($0.50)($0.50)($0.50)
Q4 20171($0.34)($0.34)($0.34)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Galena Biopharma (NASDAQ:GALE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Galena Biopharma (NASDAQ:GALE)
Insider Ownership Percentage: 2.02%
Insider Trades by Quarter for Galena Biopharma (NASDAQ:GALE)
Institutional Ownership by Quarter for Galena Biopharma (NASDAQ:GALE)
Insider Trades by Quarter for Galena Biopharma (NASDAQ:GALE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/8/2017Hudson Bay Capital ManagementMajor ShareholderSell2,363,441$0.84$1,985,290.44View SEC Filing  
2/12/2014Richard ChinDirectorSell187,500$4.33$811,875.00View SEC Filing  
2/7/2014Rudolph NisiDirectorBuy20,000$4.94$98,800.00View SEC Filing  
1/30/2014Mark SchwartzCOOSell100,000$5.57$557,000.00View SEC Filing  
1/30/2014Sanford HillsbergDirectorSell250,000$5.41$1,352,500.00View SEC Filing  
1/29/2014Rudolph NisiDirectorSell250,000$5.28$1,320,000.00View SEC Filing  
1/22/2014Steven KriegsmanDirectorSell450,000$6.52$2,934,000.00View SEC Filing  
1/17/2014Rudolph NisiDirectorSell200,000$6.90$1,380,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Galena Biopharma (NASDAQ:GALE)
Latest Headlines for Galena Biopharma (NASDAQ:GALE)
Source:
DateHeadline
americanbankingnews.com logoGalena Biopharma Inc (GALE) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 22 at 12:24 PM
americanbankingnews.com logoGalena Biopharma Inc (GALE) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 16 at 10:40 PM
finance.yahoo.com logoAbbVie and J&J Present Positive Imbruvica Leukemia Data
finance.yahoo.com - May 15 at 11:24 AM
reuters.com logoGalena Biopharma reaches $7.5 million accord in U.S. opioid probe
www.reuters.com - May 12 at 4:00 AM
americanbankingnews.com logoGalena Biopharma Inc (GALE) Posts Earnings Results, Beats Estimates By $0.13 EPS
www.americanbankingnews.com - May 11 at 9:00 PM
reuters.com logoBRIEF-Galena Biopharma Q1 loss per share $0.45
www.reuters.com - May 11 at 3:32 AM
finance.yahoo.com logoGalena Biopharma reports 1Q loss
finance.yahoo.com - May 10 at 10:30 PM
globenewswire.com logoGalena Biopharma Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
www.globenewswire.com - May 10 at 5:29 PM
finance.yahoo.com logoGalena Biopharma Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 5:29 PM
finance.yahoo.com logoJuno Therapeutics (JUNO) Posts Wider-than-Expected Q1 Loss
finance.yahoo.com - May 5 at 5:32 PM
americanbankingnews.com logo Brokerages Anticipate Galena Biopharma Inc (GALE) Will Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - May 2 at 10:52 AM
americanbankingnews.com logoGalena Biopharma (GALE) Receives Daily Media Sentiment Rating of -0.15
www.americanbankingnews.com - April 29 at 8:18 AM
americanbankingnews.com logoGalena Biopharma Inc (GALE) Sees Significant Increase in Short Interest
www.americanbankingnews.com - April 29 at 7:20 AM
americanbankingnews.com logoGalena Biopharma (GALE) Earning Somewhat Positive Press Coverage, Report Shows
www.americanbankingnews.com - April 25 at 5:30 PM
americanbankingnews.com logoGalena Biopharma Inc (GALE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 25 at 12:33 PM
finance.yahoo.com logoZacks.com featured highlights: Galena Biopharma, EVINE Live, Sanchez Production Partners, Bazaarvoice and Avon Products
finance.yahoo.com - April 21 at 11:37 AM
americanbankingnews.com logoGalena Biopharma (GALE) Receives Daily News Sentiment Rating of 0.17
www.americanbankingnews.com - April 18 at 12:17 AM
americanbankingnews.com logoGalena Biopharma (GALE) Receiving Somewhat Critical News Coverage, Study Finds
www.americanbankingnews.com - April 14 at 1:10 PM
finance.yahoo.com logoFRIDAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and ... - Yahoo Finance
finance.yahoo.com - April 13 at 5:11 PM
finance.yahoo.com logoGALE APRIL 14 ALERT: Rosen Law Firm Reminds Galena Biopharma, Inc. Investors of Important Deadline in Class ... - Yahoo Finance
finance.yahoo.com - April 13 at 5:11 PM
finance.yahoo.com logoDEADLINE TOMORROW: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm
finance.yahoo.com - April 13 at 5:11 PM
finance.yahoo.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. (GALE) & Lead Plaintiff Deadline - April 14, 2017
finance.yahoo.com - April 13 at 10:51 AM
finance.yahoo.com logoGALE APRIL 14 ALERT: Rosen Law Firm Reminds Galena Biopharma, Inc. Investors of Important Deadline in Class Action - GALE
finance.yahoo.com - April 12 at 5:25 PM
finance.yahoo.com logoFRIDAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - April 12 at 5:25 PM
americanbankingnews.com logo-$0.22 Earnings Per Share Expected for Galena Biopharma Inc (GALE) This Quarter
www.americanbankingnews.com - April 10 at 10:24 PM
reuters.com logoSEC targets fake stock news on financial websites
www.reuters.com - April 10 at 5:05 PM
News IconThe SEC is going after fake news about stocks published on financial websites
www.businessinsider.com - April 10 at 5:05 PM
finance.yahoo.com logo4-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm
finance.yahoo.com - April 10 at 5:05 PM
finance.yahoo.com logoSEC Targets Fraud on Stock Tip-Sheet Websites
finance.yahoo.com - April 10 at 5:05 PM
finance.yahoo.com logoDEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma ... - Yahoo Finance
finance.yahoo.com - April 7 at 5:17 PM
finance.yahoo.com logoGalena Biopharma Presents Positive Interim Safety Data on the NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Trastuzumab in High-Risk HER2 3+ Patients at the AACR Annual Meeting 2017
finance.yahoo.com - April 7 at 9:57 AM
finance.yahoo.com logoGalena's Breast Cancer Drug Combo Deemed Safe
finance.yahoo.com - April 7 at 9:57 AM
finance.yahoo.com logoApril 14 Deadline Alert: Law Offices of Howard G. Smith Reminds Galena Biopharma, Inc. Investors of Upcoming Lead Plaintiff Deadline
finance.yahoo.com - April 7 at 9:57 AM
finance.yahoo.com logoAPPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm
finance.yahoo.com - April 7 at 9:57 AM
finance.yahoo.com logoDEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Galena Biopharma, Inc. To Contact The Firm
finance.yahoo.com - April 7 at 9:57 AM
finance.yahoo.com logoZacks.com featured highlights: EV Energy Partners, OvaScience, Galena Biopharma, Amaya and Cenovus Energy
finance.yahoo.com - April 7 at 9:57 AM
finance.yahoo.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. (GALE) and Lead Plaintiff Deadline - April 14, 2017
finance.yahoo.com - April 7 at 9:57 AM
finance.yahoo.com logoDeadline Alert: GPM Reminds Investors of the April 14 Deadline in the Class Action Lawsuit Against Galena Biopharma, Inc.
finance.yahoo.com - April 7 at 9:57 AM
finance.yahoo.com logoDEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - April 7 at 9:57 AM
reuters.com logoBRIEF-Galena Biopharma and JGB Newton Ltd entered into waiver that amended securities purchase agreement dated May 10 - SEC Filing
www.reuters.com - April 4 at 3:38 AM
finance.yahoo.com logoGlaxoSmithKline Initiates Phase III Study with Mepolizumab
finance.yahoo.com - April 3 at 5:35 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Galena Biopharma, Inc. To Contact The Firm
finance.yahoo.com - April 3 at 5:35 PM
biz.yahoo.com logoGALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhib
biz.yahoo.com - April 3 at 5:35 PM
finance.yahoo.com logoINVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, …
finance.yahoo.com - April 1 at 1:03 PM
finance.yahoo.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Galena Biopharma, Inc. - GALE
finance.yahoo.com - March 31 at 5:25 PM
americanbankingnews.com logoGalena Biopharma Inc (GALE) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 31 at 1:14 PM
finance.yahoo.com logoRoche's Rituxan Gets FDA Advisory Committee's Recommendation
finance.yahoo.com - March 30 at 5:46 PM
us.rd.yahoo.com logoIMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - March 29 at 5:50 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. (GALE) and Lead Plaintiff Deadline - April 14, 2017
finance.yahoo.com - March 29 at 11:16 AM
finance.yahoo.com logoVertex Combo Data on Kalydeco+VX-661 Positive in Phase III
finance.yahoo.com - March 29 at 11:16 AM

Social

Chart

Galena Biopharma (GALE) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff